U.S. markets open in 4 hours 9 minutes

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.0400-0.1600 (-5.00%)
At close: 04:00PM EDT
3.0400 0.00 (0.00%)
Pre-Market: 04:17AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close3.2000
Bid3.0000 x 4000
Ask3.0400 x 4000
Day's Range3.0400 - 3.2300
52 Week Range2.7800 - 8.5800
Avg. Volume4,195,020
Market Cap325.137M
Beta (5Y Monthly)0.93
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BLUE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • bluebird bio, Inc.
    Analyst Report: Incyte CorporationIncyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Motley Fool

    Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio

    CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE) are at the forefront of developing gene therapies, yet the shares of both companies have underperformed the market over the last 12 months. CRISPR Therapeutics doesn't have any approved treatments on the market yet, but that'll change soon enough, which is the crux of the thesis in favor of it being a great growth stock. Through its partnership with Vertex Pharmaceuticals, it's aiming to commercialize the gene therapy exa-cel, which was developed to provide a functional cure for both beta-thalassemia and sickle cell disease.

  • Motley Fool

    More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics

    Gene editing is a relatively new technology that allows scientists to modify an organism's DNA. Two companies that are hard at work in this field are Bluebird Bio (NASDAQ: BLUE) and CRISPR Therapeutics (NASDAQ: CRSP). Bluebird Bio currently has two approved gene-editing therapies on the market.

  • Motley Fool

    2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street

    Investors looking for stocks that can put up dramatic gains in a short amount of time naturally flock to biotech stocks. Up and down Wall Street, the investment bank analysts have been telling anyone who'll listen to buy these biotech stocks before they soar. The average price target on these stocks suggests some dramatic gains could be up ahead.